DB:6C1

Stock Analysis Report

Executive Summary

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has CytomX Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6C1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.6%

6C1

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-54.9%

6C1

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 6C1 underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 6C1 underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

6C1IndustryMarket
7 Day7.6%-2.3%-0.2%
30 Day5.3%-3.2%0.3%
90 Day37.0%6.3%3.7%
1 Year-54.9%-54.9%8.6%8.4%17.2%13.7%
3 Year-36.6%-36.6%44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is CytomX Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CytomX Therapeutics undervalued compared to its fair value and its price relative to the market?

4.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6C1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6C1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6C1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 6C1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6C1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6C1 is overvalued based on its PB Ratio (4.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is CytomX Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

-1.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6C1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6C1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6C1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6C1's revenue (31.3% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 6C1's revenue (31.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 6C1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CytomX Therapeutics performed over the past 5 years?

-21.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6C1 is currently unprofitable.

Growing Profit Margin: 6C1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6C1 is unprofitable, and losses have increased over the past 5 years at a rate of -21% per year.

Accelerating Growth: Unable to compare 6C1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6C1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 6C1 has a negative Return on Equity (-120.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is CytomX Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 6C1's short term assets ($334.8M) exceed its short term liabilities ($76.1M).

Long Term Liabilities: 6C1's short term assets ($334.8M) exceed its long term liabilities ($214.3M).


Debt to Equity History and Analysis

Debt Level: 6C1 is debt free.

Reducing Debt: 6C1 currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: 6C1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 6C1's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6C1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 6C1 has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of -20.1% each year.


Next Steps

Dividend

What is CytomX Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6C1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6C1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6C1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6C1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6C1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Sean McCarthy (52yo)

8.5yrs

Tenure

US$5,482,233

Compensation

Dr. Sean A. McCarthy, D.Phil., has been the Chief Executive Officer and President of CytomX Therapeutics, Inc. since August 2011 and has been its Chairman since December 31, 2018. Dr. McCarthy joined the C ...


CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD5.48M) is above average for companies of similar size in the German market ($USD792.68K).

Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Sean McCarthy
Chairman8.5yrsUS$5.48m0.19% $566.4k
Frederick Gluck
Co-Founder & Director9.4yrsUS$248.54k1.17% $3.6m
W. Kavanaugh
Senior VP5.1yrsUS$1.77m0.042% $127.9k
Lloyd Rowland
Senior VP1.7yrsUS$1.94m0.026% $79.2k
Hoyoung Huh
Special Advisor to Chief Executive Officer1.2yrsUS$273.54kno data
Christopher Keenan
Vice President of Investor Relations & Corporate Communications0yrsno datano data
Sridhar Viswanathan
Senior Vice President of Process Sciences & Manufacturing Operations2.3yrsno datano data
Danielle Olander
Senior Vice President0yrsno datano data
Alison Joly
Senior Vice President of Program & Alliance Management2.1yrsno datano data
Nick Galli
Senior VP & Chief Business Officer1yrsno datano data

2.1yrs

Average Tenure

62yo

Average Age

Experienced Management: 6C1's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sean McCarthy
Chairman8.5yrsUS$5.48m0.19% $566.4k
Frederick Gluck
Co-Founder & Director9.4yrsUS$248.54k1.17% $3.6m
Elaine Jones
Director0.8yrsUS$15.56k0.00031% $946.2
Louis Weiner
Member of Scientific Advisory Board0yrsno datano data
John Scarlett
Independent Director3.7yrsUS$253.54kno data
James Meyers
Director1.2yrsUS$220.42kno data
Matthew Young
Lead Independent Director1.2yrsUS$254.79kno data
Lisa Butterfield
Member of Scientific Advisory Board0.08yrsno datano data
Charles Fuchs
Independent Director2.3yrsUS$241.04kno data
Lisa Coussens
Member of Scientific Advisory Board0.08yrsno datano data

1.2yrs

Average Tenure

61yo

Average Age

Experienced Board: 6C1's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.1%.


Top Shareholders

Company Information

CytomX Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CytomX Therapeutics, Inc.
  • Ticker: 6C1
  • Exchange: DB
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$329.398m
  • Listing Market Cap: US$305.220m
  • Shares outstanding: 45.43m
  • Website: https://www.cytomx.com

Number of Employees


Location

  • CytomX Therapeutics, Inc.
  • 151 Oyster Point Boulevard
  • Suite 400
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTMXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2015
6C1DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2015

Biography

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:03
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.